Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 117

Results For "therapies"

1514 News Found

Capnopharm to acquire operational assets of Capnomed
News | July 10, 2022

Capnopharm to acquire operational assets of Capnomed

Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.


WuXi STA opens Oligonucleotide and Peptide manufacturing facility
News | July 08, 2022

WuXi STA opens Oligonucleotide and Peptide manufacturing facility

Site Enhances New Modality CRDMO Platform Capacity for Customers


Boehringer Ingelheim, Evotec and bioMérieux forms JV Aurobac to fight antimicrobial resistance
News | July 06, 2022

Boehringer Ingelheim, Evotec and bioMérieux forms JV Aurobac to fight antimicrobial resistance

The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.


Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine
News | July 06, 2022

Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine

Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells


ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India
People | July 05, 2022

ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India

Mittal has previously managed Multiple backed Vikram Hospital as CEO and was associated with Fortis Escorts Heart Institute as zonal director.


Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918
Drug Approval | July 02, 2022

Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918

This multicenter, open-label Phase I study is designed to assess the safety and tolerability


Weizmann’s study sheds new light on a promising antidepressant
Healthcare | June 30, 2022

Weizmann’s study sheds new light on a promising antidepressant

A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression


Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3
News | June 29, 2022

Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3

Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study


Medidata launches new clinical operations technologies to address clinical trial oversight issues
Digitisation | June 28, 2022

Medidata launches new clinical operations technologies to address clinical trial oversight issues

Medidata Detect and Rave CTMS Have Improved Study Execution Through Role-Based Monitoring Workflows and Clinical Data Visualization for Hundreds of Customers Across More Than 9,000 Studies


Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
Drug Approval | June 27, 2022

Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease

The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects